LMR Partners’s Trevi Therapeutics TRVI Stock Holding History

LMR Partners’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.86M	Hold	100,000	–	–	0.01%	916
2026 Q1	$1.19M	Hold	100,000	–	–	﹤0.01%	947
2025 Q4	$1.25M	Hold	100,000	–	–	﹤0.01%	923
2025 Q3	$915K	Hold	100,000	–	–	﹤0.01%	959
2025 Q2	$547K	Hold	100,000	–	–	﹤0.01%	918
2025 Q1	$629K	Buy	+100,000	New	+$477K	0.01%	874

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

LMR Partners's TRVI Position: Q2 2026 in Review

LMR Partners held its Trevi Therapeutics (TRVI) position steady in Q2 2026 at 100,000 shares worth $1.86M. The position accounts for 0.01% of the portfolio, ranked #916.

LMR Partners first reported a position in TRVI in Q1 2025 and has held it in 6 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

LMR Partners held 100,000 shares of Trevi Therapeutics worth $1.86M as of Q2 2026.
LMR Partners left its Trevi Therapeutics share count unchanged in Q2 2026.
Trevi Therapeutics made up 0.01% of LMR Partners's portfolio in Q2 2026, its #916 holding.
LMR Partners first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 6 quarters since.
217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.